drugset / Trial / NCT04176120

Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)

NCT04176120 ↗

Phase 3 Completed 220 enrolled BioTissue Holdings, Inc
RandomizedParallel-groupSingle-blindTreatment

Summary

It is hypothesized that application at 4-week or greater intervals of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer (DFU) will, with concomitant management of infection, will result in a higher rate of wounds showing complete healing within 26 weeks of initiating therapy, compared with standard care alone. This confirmatory Phase 3 study examines a population of diabetic foot ulcer patients having adequate perfusion, with or without neuropathy, and a high suspicion of associated osteomyelitis in a complex, high grade wound.

Timeline

Start
2020-07-01
Primary completion
2024-01-25
Completion
2024-06-12

Drugs

EvaluationDrugModalityDoseRoute
Subject TTAX01 Other / unclassified — Topical

Indications